Cyclin-dependent kinase inhibitor p27(KIP1) in lymphoid tissue: p27(KIP1) expression is inversely proportional to the proliferative index

American Journal of Pathology

Volumn 151, Issue 1, 1997, Pages 151-160

  Sánchez Beato, Margarita ^b   Sáez, Ana Isabel ^b   Martínez Montero, Juan Carlos ^b   Sol Mateo, M ^b   Sánchez Verde, Lydia ^b   Villuendas, Raquel ^b   Troncone, Giancarlo ^b   Piris, Miguel Angel ^a  

^a HOSPITAL VIRGEN DE LA SALUD   (Spain)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR;

AMINO TERMINAL SEQUENCE; ARTICLE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; GENE MUTATION; GENETIC REGULATION; HUMAN; HUMAN TISSUE; LYMPHOID TISSUE; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; TUMOR SUPPRESSOR GENE;

CELL CYCLE PROTEINS; CELL DIVISION; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLIN-DEPENDENT KINASES; HODGKIN DISEASE; HUMANS; LYMPHOID TISSUE; LYMPHOMA, NON-HODGKIN; MICROTUBULE-ASSOCIATED PROTEINS; PSEUDOLYMPHOMA; TUMOR SUPPRESSOR PROTEINS;

EID: 1842331483     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Serrano M, Hannon GJ, Beach D: A new regulatory motif in cell cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993, 366:704-707
2. INK4B is a potential effector of TGF-β induced cell cycle arrest. Nature 1994, 371:257-261
3. INK4/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. Genes Dev 1994, 8:2939-2952
4. INK4. Mol Cell Biol 1995, 15:2682-2688
5. EI-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer E, Kinzler KW, Vogelstein B: WAF1, a potential mediator of p53 tumour suppression, Cell 1993, 75:817-825
6. Harper JW, Adami, GY, Wei N, Keyomarsi K, Elledge SJ: The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinase. Cell 1993, 75:805-816
7. KIP1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 1994, 78:59-66
8. Toyoshima H, Hunter T: p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 1994, 78:67-74
9. KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev 1995, 9:639-649
10. KIP2, a structurally distinct member of the Cip1 cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev 1995, 9:650-662
11. Fang F, Orend G, Watanabe N, Hunter T, Ruoslahti E: Dependence of cyclin E-CDK2 kinase activity on cell anchorage. Science 1996, 271:499-502
12. Kato J, Matsuoka M, Polyak K, Massague J, Sherr CJ: Cyclic AMP-induced G1 phase arrest mediated by an inhibitor (p27KIP1) of cyclin-dependent kinase 4 activation. Cell 1994, 79:487-496
13. KIP1 cyclin- dependent kinase inhibitor prevented by rapamycin, Nature 1994, 372:570-573
14. Kip1 for restriction point control of the fibroblast cell cycle, Science 1996, 272:877-880
15. KIP1 accumulation during the cell cycle. Science 1996, 271:1861-1864
16. KIP1 display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 1996, 85:707-720
17. KIP1-deficient mice. Cell 1996, 85:733-744
18. KIP1. Cell 1996, 85:721-732
19. Watanabe H, Fukuchi K, Takagi Y, Tomoyasu S, Tsuruoka N, Gomi K: Molecular analysis of the Cip1/Waf1 (p21) gene in diverse types of human tumors. Biochim Biophys Acta 1995, 1263:275-278
20. Shiohara M, EI-Deiry WS, Wada M, Nakamaki T, Takeuchi S, Yang R, Chen DL, Vogelstein B, Koeffler HP: Absence of Waf1 mutations in a variety of human malignancies. Blood 1994, 84:3781-3784
21. KIP1 in human malignancies, Cancer Res 1995, 55:2266-2269
22. KIP1 gene in non-Hodgkin's lymphomas and adult T-cell leukemia/lymphoma. Blood 1995, 86:1924-1930
23. Kip1 gene to 12p13 and its analysis in leukemias. Cancer Res 1995, 55:1206-1210
24. - immunophenotype associated with missense p53 mutations, J Pathol 1997, 181:51-61
25. Lutzker SG, Levine AJ: A functionally inactive p53 protein in teratocarcinoma cells is activated by either DNA damage or cellular differentiation. Nature Med 1996, 2:804-810
26. Dei Tos AP, Maestro R, Doglioni C, Piccinin S, Delia Libera D, Boiocchi M, Fletcher CDM: Tumor suppressor genes and related molecules in leiomyosarcomas. Am J Pathol 1996, 148:1037-1045
27. Chilosi M, Doglioni C, Magalini A, Inghirami G, Krampera M, Nadali G, Rahal D, Pedron S, Benedetti A, Scardoni M, Macri E, Lestani M, Menestrina F, Pizzolo G, Scarpa A: p21/WAF1 cyclin-kinase inhibitor in non- Hodgkin's lymphomas: a potential marker of p53 tumor-suppressor gene function. Blood 1996, 88:4012- 4020
28. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JKC, Cleary ML, Delsol G, De Wolf-Peters C, Falini B, Gatter KC, Grogan TM, Isaacson PG, Knowles DM, Mason DY, Muller-Hermelink H-K, Pileri SA, Piris MA, Ralfkiaer E, Warnke RA: A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994, 84:1361-1392
29. CIP1 in the maintenance of stem/progenitor cells in vivo, Blood 1996, 88:3710- 3719
30. Sánchez-Beato M, Piris MA, Martínez-Montero JC, García JF, Villuendas R, García FJ, Orradre JL, Martínez P: MDM2, and p21WAF1/CIP1, wild-type p53- induced proteins, are regularly expressed by Sternberg-Reed cells in Hodgkin's disease, J Pathol 1996, 180:58-64
31. Vindelov LL, Christensen U, Nissen NI: A detergent- trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry 1992, 13:502-509
32. Villuendas R, Piris MA, Algara P, Sánchez-Beato M, Sánchez-Verde L, Martínez JC, Orradre JL, García P, López C, Martínez P: The expression of p53 protein in non-Hodgkin's lymphomas is not always dependent on p53 gene mutations. Blood 1993, 82:3151-3156
33. Ezhevsky SA, Toyoshima H, Hunter T, Scott DW: Role of cyclin A and p27 in anti-IgM-induced G1 growth arrest of murine B-cell lymphomas. Mol Biol Cell 1996, 7:553-564
34. Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chau V, Yew PR, Draetta GF, Rolfe M: Role of the ubiquitin-proteosome pathway in regulating abundance of the cyclin dependent kinase inhibitor p27. Science 1995, 269:682-685
35. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM: The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990, 63:1129-1140